Please assess the completion status of the following clinical trial:

Trial Title: Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates who are admitted to the neonatal intensive care unit, Hat Yai Hospital during the study period.~* Neonates who were complicated with VAP due to PDR-Acinetobacter baumannii susceptible to colistin (by minimal inhibitory concentration (MIC) \< 2 mcg/dL).~Exclusion Criteria:~* Neonates who have a major anomaly or chromosomal abnormality.~* Neonates who receive colistin prior 7 days prior to study.~* Neonates who have a significant renal dysfunction defined as a serum creatinine (SCr) \>1.5 mg/dL or a decrease in urine output to \< 1 mL/kg/h;

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- Aerosolized plus intravenous colistin (Type: EXPERIMENTAL): Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
- Intravenous colistin (Type: ACTIVE_COMPARATOR): Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).